| Market Cap | 2.62B | P/E | - | EPS this Y | 23.90% | Ern Qtrly Grth | - |
| Income | -183.77M | Forward P/E | -26.19 | EPS next Y | 39.10% | 50D Avg Chg | - |
| Sales | 379.11M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 25.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | - |
| Recommedations | 2.70 | Quick Ratio | 1.30 | Shares Outstanding | 97.26M | 52W Low Chg | 252.00% |
| Insider Own | 48.61% | ROA | -18.22% | Shares Float | 50.86M | Beta | 2.15 |
| Inst Own | 56.21% | ROE | - | Shares Shorted/Prior | 8.39M/6.74M | Price | 26.98 |
| Gross Margin | 44.70% | Profit Margin | -48.47% | Avg. Volume | 1,091,060 | Target Price | 27.00 |
| Oper. Margin | -38.75% | Earnings Date | Jul 25 | Volume | 2,256,078 | Change | -0.04% |
Myovant Sciences Ltd., a biopharmaceutical company, develops redefine care for women and for men. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, which is in Phase II clinical trial for the treatment of female infertility as part of assisted reproduction. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. is a subsidiary of Sumitovant Biopharma Ltd.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Sumitomo Chemical Co., Ltd. | 10% Owner 10% Owner | Mar 10 | Buy | 27.00 | 51,599,200 | 1,393,178,400 | 45,798,176 | 03/10/23 |
| Lang Matthew | General Counsel & Co.. General Counsel & Corp. Secy. | Jan 18 | Sell | 26.89 | 1,272 | 34,204 | 354,303 | 01/20/23 |
| Merendino Lauren | Chief Commercial Off.. Chief Commercial Officer | Jan 18 | Sell | 26.89 | 2,008 | 53,995 | 169,538 | 01/20/23 |
| Marek David C | Principal Executive.. Principal Executive Officer | Jan 18 | Sell | 26.89 | 8,037 | 216,115 | 417,599 | 01/20/23 |
| Arjona Ferreira Juan Camilo | Chief Medical Office.. Chief Medical Officer | Jan 04 | Sell | 26.90 | 2,251 | 60,552 | 247,793 | 01/05/23 |
| Lang Matthew | General Counsel & Co.. General Counsel & Corp. Secy. | Jan 04 | Sell | 26.90 | 2,779 | 74,755 | 355,575 | 01/05/23 |
| Mehra Uneek | Principal Financial.. Principal Financial Officer | Dec 16 | Sell | 26.75 | 2,241 | 59,947 | 202,696 | 12/20/22 |
| Merendino Lauren | Chief Commercial Off.. Chief Commercial Officer | Oct 18 | Sell | 25.20 | 1,703 | 42,916 | 171,546 | 10/20/22 |
| Marek David C | Principal Executive.. Principal Executive Officer | Oct 18 | Sell | 25.20 | 11,156 | 281,131 | 425,636 | 10/20/22 |
| Lang Matthew | General Counsel & Co.. General Counsel & Corp. Secy. | Oct 18 | Sell | 25.20 | 1,933 | 48,712 | 358,354 | 10/20/22 |
| Arjona Ferreira Juan Camilo | Chief Medical Office.. Chief Medical Officer | Oct 18 | Sell | 25.20 | 1,604 | 40,421 | 250,044 | 10/20/22 |
| Mehra Uneek | Principal Financial.. Principal Financial Officer | Sep 16 | Sell | 18.86 | 9,243 | 174,323 | 204,937 | 09/20/22 |
| Lang Matthew | General Counsel & Co.. General Counsel & Corp. Secy. | Aug 12 | Sell | 18.23 | 31,214 | 569,031 | 363,966 | 08/16/22 |
| Lang Matthew | General Counsel & Co.. General Counsel & Corp. Secy. | Jul 18 | Sell | 12.87 | 1,935 | 24,903 | 270,400 | 07/20/22 |
| Merendino Lauren | Chief Commercial Off.. Chief Commercial Officer | Jul 18 | Sell | 12.87 | 1,704 | 21,930 | 173,249 | 07/20/22 |
| Marek David C | Principal Executive.. Principal Executive Officer | Jul 18 | Sell | 12.87 | 11,164 | 143,681 | 436,792 | 07/20/22 |
| Arjona Ferreira Juan Camilo | Chief Medical Office.. Chief Medical Officer | Jul 06 | Sell | 13.40 | 2,755 | 36,917 | 255,992 | 07/08/22 |